
doi: 10.1002/ptr.8454
pmid: 39963741
ABSTRACTThe most prevalent and bioactive cucurbitacin is Cucurbitacin B (CuB, C32H46O8), which is a tetracyclic triterpene chiefly present in the Cucurbitaceae family. CuB has a wide spectrum of pharmacological properties namely antioxidant, anticancer, hepatoprotective, anti‐inflammatory, antiviral, hypoglycaemic, insecticidal, and neuroprotective properties, owing to its ability to regulate several signaling pathways, including the Janus kinase/signal transducer and activator of transcription‐3 (JAK/STAT3), AMP‐activated protein kinase (AMPK), nuclear factor (NF)‐κB, nuclear factor erythroid 2‐related factor‐2/antioxidant responsive element (Nrf2/ARE), phosphoinositide 3‐kinase (PI3K)/Akt, mitogen‐activated protein kinase (MAPK), Hippo‐Yes‐associated protein (YAP), focal adhesion kinase (FAK), cancerous inhibitor of protein phosphatase‐2A/protein phosphatase‐2A (CIP2A/PP2A), Wnt and Notch pathways. The present review highlights the medicinal attributes of Cucurbitacin B (CuB) with special emphasis on their signaling pathways to provide key evidence of its therapeutic utility in the near future.
Humans, Animals, Triterpenes, Signal Transduction
Humans, Animals, Triterpenes, Signal Transduction
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 5 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
